Literature DB >> 11436951

Update and recommendations for the use of antipsychotics in early-onset psychoses.

K E Bryden1, N J Carrey, S P Kutcher.   

Abstract

A review was undertaken of studies evaluating the efficacy and tolerability of antipsychotic medications for the management of psychosis in children and adolescents. All identified published and unpublished studies from 1996 onward were included for review. The search located one randomized control trial, seven open-label trials, six retrospective chart reviews, and nine case reports. The studies assessed the use of haloperidol, clozapine, risperidone, olanzapine, and quetiapine in the management of psychosis in children and adolescents. Most studies reported reasonable treatment response; however, extrapyramidal side effects, sedation, and weight gain are concerning. This points to the need for appropriate baseline assessments prior to initiating treatment with these agents. Particular attention should be given to assessment of the extrapyramidal system as well as to baseline weight, lipid profile, and blood glucose. Further study is needed to refine the use of antipsychotic medications in children and adolescents in order to minimize adverse effects while conferring an optimum therapeutic response. The importance of instituting effective early treatment in youth with psychoses is an important goal that may serve to lessen the long-term morbidity of the illness.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11436951     DOI: 10.1089/104454601750284027

Source DB:  PubMed          Journal:  J Child Adolesc Psychopharmacol        ISSN: 1044-5463            Impact factor:   2.576


  2 in total

Review 1.  Benefit-risk assessment of atypical antipsychotics in the treatment of schizophrenia and comorbid disorders in children and adolescents.

Authors:  Paz Toren; Sharon Ratner; Nathaniel Laor; Abraham Weizman
Journal:  Drug Saf       Date:  2004       Impact factor: 5.606

2.  A preliminary open trial of olanzapine in paediatric acute and transient psychotic disorders.

Authors:  Vivek Agarwal; Prabhat Sitholey
Journal:  Indian J Psychiatry       Date:  2006-01       Impact factor: 1.759

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.